Prostate cancer has traditionally been diagnosed by an elevation in PSA or abnormal exam leading to a systematic transrectal ultrasound (TRUS)-guided biopsy. This diagnostic pathway underdiagnoses clinically significant disease while over diagnosing clinically insignificant disease.
to assess the role of reoxygenation of hypoxic tumor cells in hypofractionated radiotherapy of prostate cancer. the considered radiobiological model is based on the assumption of two populations (compartments) of cells: oxygenated (aerobic) cells and hypoxic cells.
βIII-Tubulin, encoded by the TUBB3 gene, is a microtubule protein. Several studies have shown that overexpression of TUBB3 is linked to poor prognosis and is involved in taxane resistance in some cancers.
The Briganti nomogram can be used with a threshold of 5% to decide when to offer lymph node dissection during radical prostatectomy. The objective of the study was to assess the accuracy of the Briganti nomogram on intermediate-risk prostate cancer patients managed in a single academic department.
The consequences of prostate cancer metastasis remain severe, with huge impact on the mortality and overall quality of life of affected patients. Despite the convoluted interplay and cross talk between various cell types and secreted factors in the metastatic process, cytokine and chemokines, along with their receptors and signaling axis, constitute important factors that help […]
Non-muscle-invasive bladder cancer (NMIBC) is usually effectively treated with transurethral resection (TUR), most often followed by intravesical instillation of bacillus Calmette-Guérin (BCG) or intravesical chemotherapy.
The 2002 National Institute for Health and Care Excellence guidance on centralisation of radical cystectomy (RC) coincided with changes in practice: use of neoadjuvant chemotherapy (NAC) and pelvic lymph node dissection (PLND), and RC for high-risk non-muscle-invasive bladder cancer (HR-NMIBC).
To determine whether transurethral en bloc submucosal hydrodissection of bladder tumours (TUEB) improves the quality of the resection compared to conventional transurethral resection (TURBT) in patients with NMIBC.
Lecture Presentation: Phillip Koo: Hi, my name is Phillip Koo from Banner MD Anderson Cancer Center in Phoenix, Arizona. Welcome back to another module in this fabulous series on precision medicine in prostate cancer. Today we have with us Dr. Stefano Fanti, who is the Director of Nuclear Medicine at the University of Bologna, in […]
Lecture Presentation: Neal Shore: Hello, and welcome to our program today. This is one of a series of modules and the title, subject of our series of really educational events is called “Precision Medicine, PSMA Targeted Therapies in Progressive Metastatic Prostate Cancer Educational Forum”. Really pleased today to have an outstanding faculty. Dr. Oliver Sartor, […]
